Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Asthma UK

- PMLiVE

NICE recommends axunio’s Axhidrox cream for adults with severe hyperhydrosis

Excessive sweating affects 1-5% of the population and can have a substantial impact on quality of life

- PMLiVE

NICE recommends treatments for mantle cell lymphoma and chronic lymphocytic leukaemia

The treatments are for eligible adults in England and Wales

- PMLiVE

Number of women in England receiving HRT on the NHS more than doubles

A record two million women were prescribed hormone replacement therapy in 2025/26 compared to 0.8 million in 2020/21

- PMLiVE

Moving Beyond the Pill: Unlocking Value Through Engaged, Empowered, and Educated Patients

True "beyond-the-pill" strategy requires shifting from a prescriptive model to a supportive one—using personalized digital tools and authentic patient voices to drive adherence, improve outcomes, and prove value.

Impetus Digital

- PMLiVE

Cases of skin cancer set to reach 263,000 in 2035 according to new report

The report forecasts a rise in cases in the US, the UK, Canada, Australia and Europe

- PMLiVE

AstraZeneca’s Trixeo recommended by CHMP for approval in EU for asthma

Asthma affects over 360 million people worldwide, including over 40 million people in Europe

- PMLiVE

Bridging the value gap: The systems, teams and mindsets that matter

In pharma, the challenge is no longer understanding what HCPs want from digital. It’s delivering it consistently. In this webinar, we explored what needs to change inside organisations to make...

Graphite Digital

- PMLiVE

NICE recommends Genmab’s Tivdak for recurrent or metastatic cervical cancer

It is estimated that 3,300 women are diagnosed with cervical cancer in the UK each year

- PMLiVE

Durbin PLC becomes Uniphar, bolstering medicine access amidst growing healthcare demands

Against the backdrop of widespread medicine shortages, Durbin PLC’s rebrand to Uniphar and integration into Uniphar | Global Sourcing represents a strategic move to address industry-wide challenges, expanding its sourcing...

Uniphar

- PMLiVE

Roche opens new Swiss Institute of Human Biology research facility

The new building is part of a 1.5bn euro site investment

- PMLiVE

Incyte Biosciences UK announces NICE approval for Opzelura for vitiligo

This is the first approved treatment option in the UK for patients with non-segmental vitiligo

- PMLiVE

Sanofi and Regeneron’s Dupixent receives positive NICE final draft guidance for COPD

Around 1.4 million people in the UK are diagnosed with COPD, with two million thought to be undiagnosed

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links